This Stepstone project aims to close the remaining gaps required for the successful launch of the BactoRelief spin-off company, ensuring it is fully prepared to attract investors and secure funding. These gaps were identified based on interactions with 9 (inter)national key opinion leaders, 2 venture capital funds and 1 business consultant. BactoRelief aims to supply the first-in-class live biotherapeutic product (LBP) for the treatment of chronic lung inflammation in millions of patients worldwide. A previously awarded IOF StarTT project enabled the development of the current lead LBP while the current Stepstone application aims to move the lead LBP to a final candidate LBP.